Reis Inc (REIS) Drops 7.05% on January 13

Equities Staff |

Reis Inc (REIS) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 7.05% to $20.95, a loss of $-1.5896 per share. Starting at an opening price of $22.24 a share, the stock traded between $20.60 and $22.99 over the course of the trading day. Volume was 20,821 shares over 260 trades, against an average daily volume of 26,556 shares and a total float of 11.25 million.

The losses send Reis Inc down to a market cap of $235.67 million. In the last year, Reis Inc has traded between $27.61 and $19.91, and its 50-day SMA is currently $23.82 and 200-day SMA is $23.60.

The stock has a P/E Ratio of 31.7.

Reis, Inc. provides commercial real estate market information and analytical tools for its subscribers, through its Reis Services subsidiary. The database contains information on apartment, office, retail and industrial properties, among others.

Reis Inc is based out of New York, NY and has some 205 employees. Its CEO is Lloyd Lynford.

For a complete fundamental analysis analysis of Reis Inc, check out’s Stock Valuation Analysis report for REIS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…